SLC5A2 and hydrops fetalis: Thanks to these results and in consideration of the fact that SGLT2-i showed no significant interaction with other HF drugs [84], a recent document from the European HF Working Group encourages the introduction of empagliflozin as soon as possible as a first-line therapy in HF patients in order to achieve the maximally tolerated optimal medical therapy in the shortest time.